Medtronic MDT Neuroscience — Research and development expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Medtronic’s 10-K, filed June 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medtronic's neuroscience — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medtronic's neuroscience — research and development expense?
- Medtronic (MDT) reported neuroscience — research and development expense of $139M in Q1 2026.
- How has Medtronic's neuroscience — research and development expense changed year-over-year?
- Medtronic's neuroscience — research and development expense decreased by 6.7% year-over-year, from $149M to $139M.
- What is the long-term trend for Medtronic's neuroscience — research and development expense?
- Over 3 years (2023 to 2026), Medtronic's neuroscience — research and development expense has grown at a 2.4% compound annual growth rate (CAGR), from $573M to $616M.
- What does neuroscience — research and development expense mean?
- Spending on developing new neuroscience products and clinical research.
- How do you interpret neuroscience — research and development expense?
- Higher spending suggests a commitment to future growth through innovation, while lower spending might indicate a focus on short-term margin expansion or a maturing product cycle.
- How does neuroscience — research and development expense compare across companies?
- Comparable to R&D intensity metrics across the medical device and pharmaceutical industries.